Munich - Delayed Quote EUR

Immunocore Holdings plc (6YG.MU)

26.40

-0.40

(-1.49%)

As of 8:00:24 AM GMT+2. Market Open.

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conf

GlobeNewswire 27 days ago

IMCR
Immunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider Love in March

We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against other stocks that are receiving the most insider investment in March. “The economy is strong overall and has made significant progress toward […]

Insider Monkey last month

IMCR
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?

Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks last month

IMCR
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH Enrollment in MAD portion of the trial continues with higher doses being evaluated (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) I

GlobeNewswire last month

IMCR
The Immunocore Holdings plc (NASDAQ:IMCR) Full-Year Results Are Out And Analysts Have Published New Forecasts

As you might know, Immunocore Holdings plc ( NASDAQ:IMCR ) recently reported its annual numbers. Revenues were in line...

Simply Wall St. last month

IMCR
Immunocore Holdings Full Year 2024 Earnings: Misses Expectations

Immunocore Holdings ( NASDAQ:IMCR ) Full Year 2024 Results Key Financial Results Revenue: US$310.2m (up 24% from FY...

Simply Wall St. last month

IMCR
Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Immunocore Holdings PLC (IMCR) reports a 30% annual revenue increase, driven by KIMMTRAK's robust performance and expanded clinical trials.

GuruFocus.com last month

IMCR
Q4 2024 Immunocore Holdings PLC Earnings Call

Q4 2024 Immunocore Holdings PLC Earnings Call

Thomson Reuters StreetEvents last month

IMCR
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) First patie

GlobeNewswire 2 months ago

IMCR
Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.

Pharma Voice 2 months ago

IMCR

LLY
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, Februar

GlobeNewswire 2 months ago

IMCR
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.

Zacks 2 months ago

IMCR
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 113.1% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 3 months ago

IMCR
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential data readouts beginning with TEBE-AM in 2026 Enrolling Phase 1/2 trial with brenetafusp combinations in ovarian and lung cancer; ongoing dose escalation with IMC-R117C (PIWIL1) and IMC-P115C (PRAME-A02-HLE) Presenting initial HIV Phase 1 MAD data in the first quarter 2025 Progressing

GlobeNewswire 3 months ago

IMCR
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a p

GlobeNewswire 3 months ago

IMCR
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune dis

GlobeNewswire 3 months ago

IMCR
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with advanced solid tumors that express PRAME (OXFORDSHIRE, England & C

GlobeNewswire 4 months ago

IMCR
Immunocore doses first subject in gastrointestinal cancer therapy trial

The therapy is the fifth ImmTAC molecule from the company to enter clinical trials.

Clinical Trials Arena 4 months ago

IMCR
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First immunotherapy program to target PIWIL1, a cancer-testis antigen overexpressed in a range of cancers, including colorectal cancer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 17 December 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage

GlobeNewswire 4 months ago

IMCR
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh

Benzinga 4 months ago

IMRX

FOLD

IMCR

Performance Overview

Return	6YG.MU	MSCI WORLD (^990100-USD-STRD)
YTD	-2.94%	-1.84%
1-Year	-50.65%	+8.74%
3-Year	-13.16%	+30.19%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immunocore Holdings plc (6YG.MU)

Immunocore to present at upcoming investor conferences

Immunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider Love in March

Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

The Immunocore Holdings plc (NASDAQ:IMCR) Full-Year Results Are Out And Analysts Have Published New Forecasts

Immunocore Holdings Full Year 2024 Earnings: Misses Expectations

Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Q4 2024 Immunocore Holdings PLC Earnings Call

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Immunocore doses first subject in gastrointestinal cancer therapy trial

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Performance Overview